Prior Authorization Leader Voluware Unveils New Company Brand, Valer®

Rebranding tied to its popular workflow automation solution by the same name

HUNTINGTON BEACH, Calif.–(BUSINESS WIRE)–Voluware formally reintroduces itself today as Valer®, taking the same brand name as its popular solution for streamlining prior authorizations and referral management. The new brand accompanies a new era of company growth, product innovation, partnership expansion, enhanced client service and more.


“Voluware was created to address the frustrations of avoidable healthcare delays and denials due to prior authorizations,” states Dr. Steve Kim, CEO and Co-founder of Valer. “Since 2012, we’ve worked towards that goal by investing in top talent and continuous product improvement, as well as partnering with thought-leading healthcare organizations and technology companies. Clients love our Valer solution, so it was natural to have our company take the same name. Valer will continue to be the gold standard for automating complex manual prior authorization workflows.”

To help lead Valer’s growth and client support, Philip Dolan joined the team as Chief Growth Officer. He is joined by Jennifer Golladay, Valer’s new VP of Client Success.

“I’ve had the privilege of working in healthcare technology for over a decade. Valer’s mission, team, technology, and culture make us uniquely equipped to address the cost and complexity that affect all of us as patients. Prior authorization management was the last manual piece of revenue cycle workflow until Valer automated it,” says Dolan. “The Valer brand—our solution and now the company—stands for faster, simpler, less stressful prior authorization management. We’re really excited about this next chapter for our clients, our partners, and our team.”

Valer’s technology speeds and simplifies the prior authorization and referral management process by automating submissions, status checking, verification, reporting, and EHR synchronization across all healthcare settings, specialties, and payers from one platform. Partnering with Valer can lead to:

  • 45% less staff time for submissions
  • 11% more staff productivity
  • 13 days extended from 5 days in authorized days out
  • 80% reduction in manual authorization processing time

The Valer team will reveal the new brand in person on January 21-24 at HFMA’s Western Symposium. Attendees interested in learning about prior authorization automation can schedule an on-site meeting here. For more information, visit valer.health.

About Valer

Founded in 2012, Valer® provides a premium solution for speeding and simplifying prior authorization and referral management for hospitals, health systems, physician practices, and other healthcare settings. With software customized for each client’s workflow and EHR, Valer enables users to automatically submit, verify, and manage prior authorizations and referrals for all payer plans from a single platform. Recognized as a 2024 AVIA Marketplace Top Prior Authorization Company, Valer improves staff productivity, financial performance, and patient satisfaction. Valer is Built Around You. For more information, visit valer.health.

Contacts

Lauren Watt

Trevelino/Keller

lwatt@trevelinokeller.com

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

5 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

6 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

6 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

7 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

9 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

9 hours ago